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Abstract: Consistent evidence from both experimental and human studies indicates that Type 2
diabetes mellitus (T2DM) is a complex disease resulting from the interaction of genetic, epigenetic,
environmental, and lifestyle factors. Nutrients and dietary patterns are important environmental
factors to consider in the prevention, development and treatment of this disease. Nutritional genomics
focuses on the interaction between bioactive food components and the genome and includes studies
of nutrigenetics, nutrigenomics and epigenetic modifications caused by nutrients. There is evidence
supporting the existence of nutrient-gene and T2DM interactions coming from animal studies and
family-based intervention studies. Moreover, many case-control, cohort, cross-sectional cohort studies
and clinical trials have identified relationships between individual genetic load, diet and T2DM.
Some of these studies were on a large scale. In addition, studies with animal models and human
observational studies, in different countries over periods of time, support a causative relationship
between adverse nutritional conditions during in utero development, persistent epigenetic changes
and T2DM. This review provides comprehensive information on the current state of nutrient-gene
interactions and their role in T2DM pathogenesis, the relationship between individual genetic load
and diet, and the importance of epigenetic factors in influencing gene expression and defining the
individual risk of T2DM.
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1. Introduction
Diabetes is considered to be one of the biggest global health burdens of the current century.
The International Diabetes Federation (IDF) Atlas 2015 [1] estimates that 415 million adults suffer from
this disease. In addition, diabetes prevalence is constantly increasing. There are three main types of
diabetes (Type 1, Type 2 and gestational diabetes). Type 2 diabetes (T2DM) is the most common type
of diabetes. According to IDF, in high-income countries, up to 91% of adults with diabetes have the
Type 2 form. The disease usually appears in adults, mostly due to an inappropriate lifestyle, however,
T2DM is increasing in children and adolescents.
T2DM is a very complex disease, for which the hallmarks are β-cell failure and insulin
resistance (IR). A combination of genetic, epigenetic, environmental, and lifestyle factors, such as
diet, are responsible for the onset and development of T2DM [2]. Genome-wide association studies
have identified many genetic variant loci involved in T2DM, however, these variants can only explain
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between approximately 10–15% of the heritability of the disease [3]. Strong evidence in the field
proposes epigenetic factors as regulators of gene expression in T2DM. Epigenetic marks might be
influenced by environmental factors that ultimately have an impact on the risk of T2DM [4].
The nutrient-gene interactions, as well as the relationship between individual genetic load
and diet play an important role in the pathophysiology of T2DM [5]. Thus, a better knowledge
of nutrigenomics and nutrigenetics of T2DM, together with a better understanding of the epigenetic
marks are instrumental in the development of precision medicine approaches to prevent, detect and
treat this disease.
In this review, we will examine the nutrient-gene interactions and their role in T2DM pathogenesis.
We will discuss how an individual’s genetic component can also impact on the risk of T2DM, depending
on the type of diet they follow. Finally, since epigenetic variations may interact through diet to influence
gene expression and define the individual risk of T2DM, we will illustrate the importance of epigenetic
factors in explaining the missing heritability cause of T2DM.
2. Effects of Nutrients on Gene Expression in the Pathogenesis of T2DM
Dietary nutrition plays an important role in the pathogenesis of T2DM, making the identification
and analysis of nutrient-gene interactions a necessary step in the understanding of this chronic disease.
Nutrigenomics, the area of nutrition that uses molecular tools to elucidate the influence of nutrients
over the genome, proteome and metabolome, provides a genetic understanding of how common
dietary components lead to up and/or down-regulation of gene(s) and changes in protein expression
levels [6]. The nutrient gene interaction may modulate the gene expression via different mechanisms:
(i) Directly; (ii) Through their metabolites; (iii) By activating various signalling molecules of complex
metabolic pathways [7].
2.1. Polyphenol-Gene Interactions in T2DM Pathogenesis
Polyphenols are a large and heterogeneous group of plant products found in fruits, vegetables,
legumes, cereals and chocolate, which may be further classified into flavonoids, lignans, phenolic
acids, and stilbenes [8]. Numerous studies have reported beneficial effects of polyphenol-rich foods in
lowering the risk of T2DM and improving inflammation and glycaemia markers in Type 2 diabetic
subjects [9,10]. Dietary polyphenolic compounds may exert hypoglycemic effects in multiple ways,
such as diminished carbohydrate digestion and glucose absorption, inhibition of glucose release,
stimulation of insulin secretion and protection of pancreatic β-cells against glucotoxicity, increased
glucose uptake in peripheral tissues by modulating intracellular signalling, antioxidant activity and
inhibition of advanced glycation end product formation [9,11,12].
2.1.1. Flavonoid-Gene Interactions in DM Pathogenesis
Dietary flavonoids include flavones, flavonols, flavanols, flavanones, isoflavones, and anthocyanins.
Numerous studies strongly support the protective effects of polyphenols on glucose homeostasis,
and on some specific molecules such as flavanols, quercetin, luteolin and others that have been shown
to impact on different steps of intracellular signalling pathways (insulin secretion, insulin signalling
and glucose uptake, enhancing mitochondrial status, suppression of inflammatory cytokine production
and reactive oxygen species (ROS)/reactive nitrogen). In addition, flavonoids, in a similar way to
phenolic acids and tannins, have the property of inhibiting the α-glucosidase and α-amylase enzymes
responsible for carbohydrate digestion [9,11–15].
Consistently, human urinary excretion studies on T2DM case-controlled pairs selected from the
Nurses’ Health Study (NHS) and NHSII have indicated that specific flavonoids, including flavanones
(naringenin and hesperetin) and flavonols (quercetin and isorhamnetin), as well as the phenolic acid,
caffeic acid, but not flavan-3-ols and ferulic acid, were associated with a lower risk of developing T2DM
in a time-dependent manner [16]. In an average 8.8 year follow-up study in women after ingestion
of total or individual flavonoids and flavonoid-rich foods it was shown that whereas total flavonols
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and flavones, quercetin, kaempferol, myricetin, apigenin, and luteolin did not significantly increase
diabetes risk, apple or tea consumption was inversely associated with T2DM risk [17]. This is in
accordance with the Health Professionals Follow-Up Study which also found that higher consumption
of anthocyanins, particularly from pears, apples and blueberries, but not total flavonoid intake or other
flavonoid subclasses, were inversely associated with T2DM [18]. By contrast, the Iowa Women’s Health
prospective cohort study in postmenopausal women suggested that only food constituent flavonoid
consumption was not associated with diabetes risk. However, in the same study, regular consumption
of red wine, white wine, beer, and liquors was inversely associated with diabetes, suggesting that it is
the alcohol per se and not the polyphenols which may protect against diabetes [19]. The conflicting
results of those studies might be a consequence of the difficulties in evaluating the contribution of
other dietary constituents, or improper timing and quality of dietary assessment.
Flavan-3-ols are present in fruit, tea, cocoa and chocolate (Table 1). Catechins are flavanols
compounds present mainly in green tea. In streptozotocin (STZ)-induced diabetic rats, catechin
hydrate treatment reduced the elevated level of serum glucose and prevented vascular endothelial
dysfunction through the activation of endothelial phosphatidylinositol 3-kinase (PI3K) signal and
subsequent activation of eNOS signalling systems [20].
One of the most common flavanols is epigallocatechin gallate (EGCG). In rats, EGCG has been
demonstrated to affect numerous processes, including more efficient insulin secretory function,
increased viability of β-cells under conditions of glucotoxicity, glucose uptake and tolerance, IR,
oxidative stress, inflammation and mitochondrial function. These effects of EGCG involved augmented
insulin receptor substrate-2 (IRS2) signalling, although other mechanisms might be relevant too.
The reductive glucolipotoxic effect of EGCG occurs through the incrementation of AMP-activated
protein kinase (AMPK) signalling to inhibit the activities of lipogenic enzymes and ameliorate
mitochondrial function [21]. Similarly, the positive effects of EGCG on IR in dexamethasone-induced
rat L6 cells was essentially dependent on the AMPK and PI3K/Akt activation pathway [22], while
in differentiated rat L6 myotubes, EGCG and epicatechin enhanced insulin-mediated glucose uptake
in vitro and translocation of glucose transporter (GLUT) 4 [23]. EGCG has also been shown to protect
insulin-producing β-cells from pro-inflammatory cytokine-induced cytotoxicity via the modulation of
B cell CLL/lymphoma 2 (BCL-2) expression [24].
In animal studies, EGCG supplementation (1% in diet) in obese db/db mice improved glucose
tolerance, increased glucose-stimulated insulin secretion from pancreatic β-cells and preserved islet
morphology by reducing the expression of the endoplasmic reticulum stress-associated islet marker
genes DNA-damage inducible transcript 3 (Ddit3) and its downstream target protein phosphatase 1,
regulatory subunit 15A (Ppp1r15a), as well as cyclin-dependent kinase inhibitor 1A (Cdkn1a) [25]. In rodent
models of T2DM, EGCG enhanced oral glucose tolerance in severely diabetic mice and in moderately
diabetic rats, and increased glucose-stimulated insulin secretion. EGCG upregulated glucokinase, acyl
CoA oxidase-1 (ACO-1) and carnitine palmitoyl transferase-1 (CPT-1) mRNA expression in liver and
adipose tissues of obese db/db mice in a dose-dependent manner. Conversely, exposure of H4IIE
hepatoma cells to EGCG decreased the expression of genes involved in gluconeogenesis and the
synthesis of fatty acids, triacylglycerol and cholesterol, whereas genes involved in glucose transport
(Glut 1) and glycolysis (phosphofructokinase) were induced in [26].
In humans, results from epidemiological studies on EGCG are contradictory. Whereas some
studies have demonstrated that an acute, high dose of EGCG concentrated green tea supplement could
control postprandial hyperglycemia [27], long-term studies in Type 2 diabetic adults did not reveal a
hypoglycemic effect [28]. A recent meta-analysis of clinical human studies with catechins in controlled
trials on glycemic control showed that green tea catechins (EGCG) reduced fasting glucose over a
median of 12 weeks, whereas fasting insulin, glycated haemoglobin (HbA1c), and homeostatic model
assessment of IR (HOMA-IR) were not affected [29].
Naringin and hesperidin, the two major flavanones, are present in citrus fruits and also
have hypoglycemic and hypolipidemic action in T2DM by partly regulating the fatty acid and
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cholesterol metabolism and affecting the gene expression of glucose-regulating enzymes (Table 1).
In C57BL/KsJ-db/db mice, both hesperidin and naringin significantly increased hepatic glucokinase
mRNA level via peroxisome proliferator-activated receptor gamma (PPAR-γ) and upregulated
adipocyte Glut 4. Naringin also lowered hepatic mRNA expression of phosphoenolpyruvate
carboxykinase PEPCK and glucose-6-phosphatase G6Pase [30].
T2DM rats fed a high-fat diet (HFD) and administered low-dose STZ injection naringin, were
shown to improve β-cell function, ameliorating hyperglycemia, hyperinsulinemia and IR by increasing
PPAR-γ and heat shock proteins (HSP) expression in the livers of diabetic rats [31]. Despite this
promising data, more clinical studies in humans to support the anti-diabetic potential of these
flavanones are necessary.
The most abundant flavonoids are flavonols, which are widely distributed throughout plant-based
foods. Quercetin is one of the most important dietary flavonols and is found in red wine and numerous
fruits, vegetables and nuts (Table 1). The Protective effects of quercetin have been related to decreasing
oxidative stress with preservation of pancreatic β-cell integrity in STZ-induced diabetic rats, possibly
by decreasing lipid peroxidation, nitric oxide (NO) production and by increasing antioxidant enzyme
activity [32]. In addition, quercetin seems to be beneficial for the treatment of diabetic neuropathy as it
has been shown to protect cultured dorsal root ganglion neurons of rats against high glucose-induced
apoptosis via Nrf-2/HO-1 activation and nuclear factor kappa B (NF-κB) inhibition [33]. The inhibitory
effect on inflammatory pathways (activation of NF-κB signalling and reduction in serum level of both
TNF-α and C-reactive protein (CRP)) without affecting glucose levels, would explain the potential of
quercetin to prevent diabetic vascular complications in both animal models with insulin deficiency
and resistance by its anti-inflammatory effect rather than its metabolic effects [34]. In a different study,
dietary supplementation with 0.5% quercetin in the diet for 2 weeks in STZ-induced T2DM BALB/c
mice decreased blood glucose and enhanced serum insulin concentrations by inhibiting expression of
cyclin-dependent kinase inhibitor p21 (WAF1/Cip1) (Cdkn1a) associated with cell proliferation in the liver
and pancreas [35].
Quercetin also showed anti-inflammatory effects in male C57Bl/6j mice and obese Zucker rats.
In male C57Bl/6j mice, supplementation with 0.8% quercetin in a HFD for 8 weeks decreased
the circulating markers of inflammation interferon-gamma (IFN-γ), interleukin-1alpha (IL-1α),
and interleukin-4 (IL-4) [36]. In obese Zucker rats, administration of both 2 and 10 mg/kg of body
weight of quercetin for 10 weeks improved dyslipidemia, hypertension, and hyperinsulinemia, but
only the highest dose of quercetin produced anti-inflammatory effects as it increased the plasma
concentration of adiponectin, reduced NOx levels in plasma and lowered TNF-α production in visceral
adipose tissue [37].
The hypoglycemic effects of the major dietary flavones apigenin and luteolin, found in celery, parsley
and many herbs, may be related to the protection of pancreatic β-cells against glucotoxicity (Table 1).
In addition, together with quercetin, apigenin, and luteolin protected RINmF5 cells from cytokine-induced
pancreatic-cell damage by inhibiting inducible nitric oxide synthase (iNos) gene expression through
suppression of NF-κB activation, and also prevented IL-1β- and IFN-γ-mediated inhibition of insulin
secretion [38]. However, it is not clear whether this effect also occurs in the islets in vivo.
The major dietary isoflavones are daidzein and genistein which are primarily present in soybeans,
soy foods and legumes, and have been shown to reduce hyperinsulinemia (Table 1). Studies in rats with
diet-induced obesity showed that soy isoflavones in a HFD significantly stimulated insulin secretion,
decreased PPAR-γ, GLUT 2, and SREBP-1 expression, and ameliorating hyperinsulinemia observed
during obesity [39]. In STZ-induced diabetic mice, dietary intake of genistein significantly improved
hyperglycemia, glucose tolerance, and circulating insulin levels, preserving islet β-cell proliferation,
survival, and mass. The insulin-secreting activity and proliferative effect of genistein in pancreatic β-cells is
mediated, at least partially, via activation of the cAMP/PKA-dependent ERK1/2 signalling pathway [40].
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In humans, the antidiabetic effect of the isoflavones is still poorly known. However, data from a
human study showed that genistein administration at 54 mg/day in postmenopausal women decreased
fasting glucose and increased glucose tolerance and insulin sensitivity [41].
Previous studies have shown that anthocyanins and anthocyanidins stimulate insulin secretion
and have protective effects on β-cells in vitro (Table 1) by stimulating important factors for insulin
gene transcription and reducing reactive oxygen species (ROS)-mediated apoptosis and necrosis [42].
Intake of anthocyanins in T2DM mouse models was found to inhibit elevation of blood glucose levels
and improve insulin sensitivity. The antidiabetic effects of anthocyanins were likely mediated by
upregulation of solute carrier family 2 members 4 (Slc2a4) (gene encoding for GLUT 4 transporter),
down-regulation of retinol-binding protein and the related inflammatory adipocytokines [43] Similar
results were obtained when T2DM mice received a dietary bilberry extract rich in anthocyanins. These
mice displayed AMPK activation and Slc2a4 in white adipose tissue while in liver glucose production
and lipid content were suppressed. Inactivation of acetyl-CoA carboxylase and upregulation of PPAR-α,
acyl-CoA oxidase, and carnitine palmitoyltransferase-1A were also observed in the liver of TD2M
mice fed with anthocyanins [44]. In humans, consumption of anthocyanin-rich foods, particularly
blueberries and apples or pears, was associated with a lower risk of T2DM, without a significant
association between total flavonoid intake or other types of flavonoids [18].
Table 1. Flavonoids-gene interactions in the development of type 2 diabetes (T2DM).
Flavonoids Genes and GeneProducts Affected Function Experimental Model Reference
Flavan-3-ols







↑ Viability of β-cell,
↑ Insulin secretion RIN-m5F cells [21]
↑ AMPK
↑ PI3K/Akt pathway ↓ IR
dexamethasone-induced
rat L6 cells [22]
↑ PI3K phosphorylation ↑ Glucose uptake differentiated ratL6 myotubes [23]






preserve islet structure db/db mice [25]
↑ Glucokinase,















↓ Hyperglycemia C57BL/KsJ-db/db mice [30]












HFD-STZ-induced T2D rats [30]
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Table 1. Cont.
Flavonoids Genes and GeneProducts Affected Function Experimental Model Reference
Flavonols
quercetin ↑ Antioxidant enzyme activity↓ Nitric oxide (NO) production
↓ Lipid peroxidation,






neurons of rats [33]
↓ Cdkn1a
↓ Hyperglycemia,
↑ Insulin plasma levels
↑ Pancreatic cell
proliferation





of inflammation C57Bl/6j mice [36]
↑ adiponectin,





obese Zucker rats [37]
Flavones















rats and pancreatic islets of
rats in a HFD [39]
genistein ↑ cAMP/PKA-dependent ERK1/2signalling pathway
↓ Hyperglycemia
↑ Glucose tolerance,
↑ Insulin plasma levels
↑ β-cell preservation
STZ-induced DM mice [40]
Anthocyanins
↑ heme oxygenase-1 (HO-1) gene




pancreatic β INS-1 cells
and primary islets [42]
↑ Glut 4
↓ retinol binding protein 4 (RBP4)
↓ Hyperglycemia









↑ Insulin sensitivity T2D KK-A(y) mice [44]
2.1.2. Phenolic Acid-Gene Interactions in T2DM Pathogenesis
The most common phenolic acids are caffeic acid, chlorogenic acid (the major phenolic compound
present in coffee) and ferulic acid (which is esterified to hemicelluloses in cereals) [14].
Most of the epidemiological studies showed an inverse association of caffeinated, decaffeinated
coffee and caffeine intake with T2DM in a dose-response manner (1–6 cups/day), compared with no or
rare coffee consumption, supporting the hypothesis that habitual coffee consumption is associated with
a substantially lower risk of T2DM [45,46]. Regarding tea intake, several meta-analyses also reported
potential beneficial effects, although it is not clear whether they are in a dose-response manner [47–50].
These beneficious effects on T2DM include an association with decreased IR [50,51], but not with
increased insulin secretion and postprandial effects rather than in fasting glucose metabolism [52,53].
The protective effects of coffee consumption on T2DM involve multiple mechanisms. Recent
studies have suggested that chlorogenic acid produced from caffeic acid and quinic acid reduces
the ability to inhibit α-amylase and α-glucosidase activities, which are key enzymes linked to
T2DM [54]. In mouse preadipocyte 3T3-L1 cells, coffee reduced the accumulation of lipids during
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differentiation and inhibited the expression of differentiation marker genes such as PPAR-γ, adiponectin,
CCAAT-enhancer-binding protein alpha (C/EBPα), Glut 4, and lipoprotein lipase (LPL) [55]. In db/db mice,
chlorogenic acid has been suggested to lower the levels of fasting plasma glucose and HbA1c during
late diabetes through an adiponectin receptor signalling pathway, elevating the adiponectin level
in visceral fat and the adiponectin receptors in the liver and muscles. In addition, chlorogenic acid
would inhibit gluconeogenesis by down-regulating hepatic glucose-6-phosphatase (G6Pase) activity,
increasing glucose transport in skeletal muscles via up-regulation of AMPK and improving disordered
lipid metabolism via up-regulation of hepatic PPAR-α [56].
Regarding ferulic acid, previous studies have reported an important antioxidant activity and
hypoglycemic effect in different T2DM diabetic mice models. In high fat and fructose-induced
Type 2 diabetic rats, ferulic acid restored normal glucose homeostasis, improving insulin sensitivity
and hepatic glycogenesis and inhibiting gluconeogenesis and the expression of insulin signalling
inhibitors, such as the gluconeogenic enzyme genes PEPCK and G6Pase [57]. Besides restoring blood
glucose, serum insulin, glucose tolerance and insulin tolerance to a normal range, it also reduces the
over-expression of hepatic solute carrier family 2 (facilitated glucose transporter), member 2 Slc2a2 (which
encodes for glucose transporter GLUT 2) by impairing the binding of SREBP1c, HNF1α and HNF3β
transcription factors with the Slc2a2 promoter [58].
2.1.3. Other Bioactive Compound-Gene Interactions in T2DM Pathogenesis (Polyphenols)
Numerous studies support the effect of resveratrol (trans-3,5,4′-trihydroxystilbene), found in
grapes, peanuts, blueberries and red wine, in reducing diabetic complications in many organs
and tissues including liver and pancreatic β-cells and in different animal models of diabetes [59].
Other effects include the improvement of glucose homeostasis, a decrease in IR, the protection of
pancreatic β-cells, an improvement in insulin secretion and an amelioration of metabolic disorders [60].
Resveratrol may act as an anti-inflammatory molecule in diabetes and other chronic diseases associated
with chronic activation of NF-κB, blocking the NF-κB-dependent expression of the inflammatory
cytokines IL-6, IL-8, and MCP-1 [61]. In addition, resveratrol may prevent diabetes by augmenting
brain-derived neurotrophic factor (BDNF), when levels are low in T2DM, and may enhance production
of the anti-inflammatory lipid, lipoxin A4 [62]. Another potential mechanism may be by inducing
resveratrol-mediated changes in the gut microbiome, as recent studies in obese mice suggested, showing
that faecal transplantation from healthy resveratrol-fed donor improved glucose homeostasis [63].
Controversy arises when human clinical studies are considered. Although some studies have not
found clear effects [64,65], many others have described the beneficial actions of resveratrol. In obese
insulin-resistant adults after four weeks of resveratrol treatment, it has been observed that postprandial
glucose decreased and glucose tolerance was not dose-dependent [66]. In Type 2 diabetic subjects,
resveratrol supplementation significantly improved fasting blood glucose, HbA1c, total cholesterol,
triglyceride, and low density lipoprotein concentrations. The intake of resveratrol also decreased IR and
oxidative stress and improved insulin signalling via the AKT pathway in Type 2 diabetic subjects [67,68].
Curcumin in addition to resveratrol has recently been suggested as a potential bioactive
product in the field of diabetic nutrition. Treatment with either curcumin (1–100 pM) or resveratrol
(0.1–10 µM) was reported to enhance pancreatic β-cell function, promoting insulin secretion in mouse
β-cell lines as well as in human islets. In both humans and mice, curcumin might be acting as
an inhibitor of phosphodiesterases, which degrades cAMP and cGMP, and therefore improves
islet insulin secretion [69]. A 9-month study of curcumin treatment in a pre-diabetic population
appeared to improve overall function of β-cells, indicated by an increased HOMA-β and reduced
C-peptide, and significantly prevented T2DM development in the pre-diabetic population. In addition,
curcumin intervention significantly increased adiponectin levels, which is inversely correlated to
the T2DM risk [70]. Previous studies have also shown an anti-inflammation activity of curcumin by
downregulating other inflammatory cytokines, such as tumor necrosis factor-alpha (TNF-α), leptin
and resistin, because the inhibition of the transcription factors NF-κB and Wnt/β-catenin and the
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activation of peroxisome proliferator-activated receptor-γ and Nrf2 cell-signalling pathways [71]. This
regulation would lead to its antidiabetic effect on IR, hyperglycemia, and hyperlipidemia.
Despite the many beneficial actions of curcumin and resveratrol, controversy rises when human
clinical studies are considered [64,65]. Poor solubility and absorption of resveratrol when given orally
and poor curcumin stability under certain cell culture conditions emphasize the need to optimise the
experimental set-up.
2.2. Vitamin-Gene Interactions in T2DM Pathogenesis
Vitamin D deficiency affects insulin secretion, IR, and β-cell dysfunction since it modifies the
expression of numerous genes involved in immune responses, chemotaxis, cell death and pancreatic
β-cell function/phenotype [72,73]. Administration of vitamin D improves impaired glucose tolerance and
insulin secretion in vitamin D deficient rats by modulating the generation and effects of cytokines [74].
In addition, vitamin D enhances insulin sensitivity by stimulating the expression of insulin receptors [75]
and by promoting the expression of PPAR-δ [76] (Table 2). Furthermore, vitamin D decreases the effects
of systemic inflammation in T2DM and protects against β-cell cytokine-induced apoptosis by directly
modulating the expression and activity of cytokines affecting IR, such as IL-1, IL-6, and TNF-α in monocytes
from T2DM patients [77]. Some studies support the indirect effects of vitamin D on β-cell function via its
well-recognised role in regulating extracellular calcium and calcium influx [78].
In humans, lower vitamin D levels represent a risk factor for incident T2DM [79] and hypovitamin
D levels with increased parathyroid hormone (PTH) levels seems to be an independent predictor
of β-cell dysfunction, IR and glycemia [80]. Patients with T2DM with established hypovitaminosis
improve glycaemia and insulin secretion by Vitamin D replenishment, not only through a direct action
on pancreatic β-cell function but also via regulation of plasma calcium levels, which regulate insulin
synthesis and secretion [81,82]. Currently, some clinical trials have suggested the combined effects
of vitamin D and calcium supplementation for an improvement in the glycemic status of vitamin
D insufficient diabetic patients [83]. However, a study selection trial that compared vitamin D3
supplementation with placebo or a non-vitamin D supplement in adults with normal glucose tolerance,
prediabetes, or T2DM showed no effect of vitamin D3 supplementation on glucose homeostasis
or diabetes prevention. The moderate degree of heterogeneity among subjects and the short-term
follow-up duration of this trial could make the potential effects of vitamin D3 supplementation in
diabetic patients inconclusive [84,85].
Vitamin A is essential for pancreas development, islet formation and function [86]. However,
there is controversy about the effectiveness of vitamin A, retinol and its carrier proteins, retinol binding
protein (RBP) and transthyretin for treating diabetes since the effects on insulin secretion seem to
be dependent on its metabolites. Retinoic acid is a potent inductor of pancreatic differentiation [87].
Vitamin A (all-trans-retinol) is required for both maintenance of pancreatic β-cell and α-cell mass and
for glucose-stimulated insulin secretion in adult mice [88], although studies on the use of supplements
in T2DM humans have shown inconclusive results [89]. RBP might affect glucose homeostasis through
the activity of GLUT. This is supported by the observation that, enhanced serum RBP4 levels appear
to be a trigger for the development of systemic IR both in animal models and in humans [90,91].
Moreover, the antioxidant properties of carotenoids (pro-vitamin A compounds) may also protect
against T2DM [92], although previous studies found little evidence for an association between dietary
intake of lycopene, a powerful antioxidant carotenoid compound, and the risk of T2DM in women [93].
Regarding the antidiabetic effects of Vitamin E and tocopherols, although results from animal
studies suggested an association between Vitamin E consumption and a lower risk of T2DM [94],
several randomised interventional clinical trials not only failed to confirm that there was a beneficial
effect in preventing or treating T2DM but suggested an aggravation of some diabetes affections [95–97].
Biotin is also required for the normal expression of critical carbohydrate metabolism genes and
for glucose homeostasis, such as forkhead box A2 (Foxa2), the pancreatic and duodenal homeobox factor
transcription factor (Pdx1), hepatocyte nuclear factor 4alpha (Hnf4α), insulin (Ins), glucokinase (Gck), Calcium
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Voltage-Gated Channel Subunit Alpha1 D (Cacna1d) and acetyl-CoA carboxylase [98] (Table 2). In the
Type 2 diabetic rat model induced by HFD and low-dose of STZ, biotin supplementation exerted
antioxidant, anti-hyperlipidaemic, anti-inflammatory and anti-hyperglycaemic effects, increasing the
level of insulin, probably through modulation of PPAR-γ, IRS-1 and NF-κB proteins [99].
The role of ascorbic acid in diabetes treatment remains unclear since it can also be a pro-oxidant
under certain in vitro conditions and it can glycate proteins despite its beneficial preventive antioxidant
properties. In vitro studies suggested that appropriate concentrations of vitamin C in pancreatic
β-cells may have beneficial effects since the number of α- and β-cells increased after vitamin C
supplementation [100]. Different studies have found lower levels of ascorbic acid in the plasma of
diabetic patients and experimental diabetic animal models [101,102] and a strong inverse association
between plasma vitamin C levels and T2DM risk [103]. Administration of a high dose of vitamin C
inhibited insulin secretion in rat islets in a dose-dependent manner [104].
Clinical trials of vitamin C supplementation in diabetic populations have shown controversial
results. In some Type 2 diabetic patient studies, administration of vitamin C increased plasma vitamin
C levels and whole body glucose disposal thus improving both fasting blood glucose and HbA1c
levels [105,106]. However, in others, administration of oral vitamin C was unable to completely replenish
the plasma level of vitamin C and did not improve endothelial dysfunction or IR [107] or even suggested
that supplements of vitamin C may actually increase the risk of cardiovascular disease mortality [108].
Despite their antioxidant properties and effects in the reduction of diabetic complications in
diabetic mice models [109], supplementation of B vitamins in general has not been proposed for the
primary prevention of T2DM. In fact, recent studies have suggested that long-term exposure to high
levels of the B vitamins niacin, thiamin and riboflavin may correlate with prevalence of obesity and
diabetes. In fact, niacin may induce glucose intolerance, IR and liver injury [110]. Furthermore, it has
been observed that riboflavin in non-toxic doses prevents cytokines-induced p38 phosphorylation and
IL-6 upregulation on insulinoma NIT-1 cells and isolated rodent islets [111]. Nicotinamide, known
to promote differentiation of mouse embryonic stem cells into insulin producing cells [112–114], also
induced insulin gene expression by increasing v-maf avian musculoaponeurotic fibrosarcoma oncogene
homolog A (MafA) expression in INS1-1 β-cells [115] (Table 2).
Table 2. Vitamin-gene interactions in the development of T2DM.
Vitamins Genes and GeneProducts Affected Function Experimental Model References
vitamin D
↑ Human insulin
receptor gene ↑ Insulin sensitivity U-937 human promonocytic cells [75]










↑ Foxa2, ↑ Pdx-1
↑ Hnf-4α
↑ Ins, ↑ Gk,
↑ Cacna1d, ↑ Acac
↑ Insulin secretion








T2DM rat model induced by high-fat
diet (HFD) and low-dose STZ [99]
Riboflavin
↓ IL-6 upregulation ↓ Cytokines-inducedp38 phosphorylation
Insulinoma NIT-1 cells and
isolated rodent islets [111]
Nicotinamide
↑MafA ↑ Insulin synthesis INS-1 cells, pancreatic islets [115]
↑ Pdx-1 Pancreatic β-celldifferentiation Mouse embryonic stem cells [112–114]
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2.3. Amino Acid-Gene Interactions in T2DM Pathogenesis
Dietary protein and amino acids also modulate insulin secretion and/or contribute to the
maintenance of β-cell function [116,117]. The mechanisms function by influencing gene and protein
expression in pancreatic islets and activating the PI3K/PKB/mTOR pathway, which results in
improved insulin release [118,119]. In this respect, it has been suggested that dietary components
of germinated brown rice improves glycemic control by downregulating the gluconeogenic genes
Fbp1 and Pck1 in Type 2 diabetic rats [120]. In general, the mechanisms proposed for the amino acid
effects on glucose homeostasis and blood glucose control included a direct insulinotropic effect on
insulin secretion from the β-cell, the role of precursors for liver glucose synthesis, and a potential
effect on insulin signalling [121]. Recent studies have suggested that supplementation with casein
hydrolysate would attenuate the NLRP3-ASC inflammasome activity, a molecular platform mediating
the processing of IL-1β in response to infection and stress conditions, improving insulin sensitivity
and glucose tolerance in vitro and in mice fed with HFD [122].
Overall, the role of dietary protein on glucose control through endogenous production of glucose
varies depending on the experimental conditions, the protein and carbohydrate content of the meal
and the window of metabolic investigation after the meal. In T2DM patients, protein ingestion
augmented postprandial insulin release and led to the attenuation of postprandial elevation in
circulating glucose concentration [123,124]. Regarding the effects of animal protein intake on T2DM
risk, several prospective cohort studies have found associations between animal protein intake and
T2DM risk highly dependent on the source and type of animal protein and presence of others food
components. Epidemiological studies indicate that higher intake of low-fat and fat-free fermented
dairy foods are associated with lower T2DM risk [125–127] but more epidemiological evidence is
necessary to elucidate the real association among intake of protein supplements and T2DM risk.
Amino acids are potentiators of glucose-induced insulin release [117] promoting slow cytosolic
calcium oscillations in mouse pancreatic islets [116]. Four amino acids, namely arginine, leucine,
isoleucine and valine are largely responsible for the observed effects. Branched-chain amino acids
(BCAAs) isoleucine, leucine and valine are important as nutrient signals and metabolic regulators [128].
Epidemiological studies have shown that BCAAs plasma concentrations and metabolism are altered
in T2DM. In obese and T2DM animal models, low circulating levels of adiponectin impair the
BCAAs catabolism, which leads to accumulation of these amino acids through a down-regulation of
mitochondrial phosphatase 2C (PP2Cm) expression mediated by the AMPK signalling pathway [129].
Increased plasma BCAAs have been associated with IR and levels of HbA1c. Accumulation of
BCAAs has been suggested to promote mitochondrial dysfunction, linked to stress kinase stimulation
and β-cell apoptosis which are frequently related to IR and T2DM. Furthermore, elevated circulating
BCAAs levels have been found to be a reliable prediction of TDM2 especially in Caucasians and
Hispanics and not only in presymptomatic individuals, but also in those classified as prediabetic or
diagnosed as Type 2 diabetic [130–132]. Despite the numerous studies, it is not clear yet whether
increased BCAAs levels are simply markers of IR or whether they are direct contributors to IR and loss
of action [133–136].
Among BCAAs, L-leucine is unique in inhibiting NO synthesis from L-arginine in endothelial
cells, activating glutamine: fructose-6-phosphate aminotransferase (GFAT) [137] and may modulate
cardiovascular homeostasis in IR activating the mechanistic target of rapamycin (serine/threonine
kinase) (mTOR) complex, a key regulator in cell growth and proliferation [138–140]. Leucine also
appeared to enhance pancreatic β-cell insulin secretion by its ability to allosterically activate glutamate
dehydrogenase, which has also been reported for other amino acids, such as phenylalanine [141].
Despite numerous studies having suggested a causal role of high levels of BCAAs in impairing
insulin signalling or IR [142,143], other observations indicate that BCAAs activation of the mammalian
target of rapamycin complex 1 (mTORC1), which generates an inhibitory feedback loop on insulin
receptor substrate proteins, is not necessary or sufficient to trigger IR [144]. Recent work using
untargeted metabolomics in a T2DM rat model consistently found that BCAA levels were not elevated
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until six months post-onset of diabetes, supporting the idea that the increase in BCAA level is not
enough to elicit IR and T2DM in that model [145].
Elevated circulating levels of the aromatic amino acids phenylalanine and tyrosine have also
been linked to the development of T2DM, acting as indirect markers of insulin sensitivity, not only in
T2DM patients but also in presymptomatic individuals [130,131,146–148]. On the other hand, in those
clinical trials, glycine was found to be reduced, possibly due to an increase in the gluconeogenesis or
glutathione consumption by increased oxidative stress [130,146,147,149,150].
The insulinotropic effect of arginine in the presence of glucose could be explained by directly
depolarising the plasma membrane of β-cells, activating the Ca2+ channels resulting in the influx of
Ca2+ which triggers insulin exocytosis [116,151].
Arginyl-fructose, which is widely distributed in red ginseng, has antidiabetic effects attributed
to it by suppressing carbohydrate absorption in the gastrointestinal tract [152]. Arginyl-fructose has
potential as a pharmacological agent for glycemic control since it significantly reduces postprandial
blood glucose levels in rodents and humans. In contrast, glucose-related biomarkers including
HbA1, insulin, and C-peptide levels were not significantly improved by dietary supplementation with
arginyl-fructose [153,154].
2.4. Dietary Fat-Gene Interactions and Their Role in T2DM
Although numerous qualitative analyses on the intake of different types of fat have found
inconsistent associations between intake and T2DM risk [155,156], consumption of a high fat diet (HFD),
mainly in saturated fatty acids (SFAs), is believed to be associated with an increased risk of T2DM.
In addition, a correlation between a higher intake of SFAs and decreased insulin sensitivity has been
demonstrated in several cross-sectional studies [125,157–159]. In animal models, an increase in plasma
fatty acid concentration is associated with an increase in intracellular fatty acyl-CoA and diacylglycerol
concentrations. As a consequence, insulin activation of IRS-1 and IRS-1-associated PI3-kinase activity
is inhibited, resulting in a decrease in insulin-stimulated glucose transport activity [160]. In addition,
T2DM C57BL/6J mice fed with HFD upregulated proteins involved in pancreatic β-cell proliferation
and downregulation of glutathione peroxidase gene (Gpx1) implicated in the antioxidant defenses
of β-cells and in the regulation of MafA expression, which is important in the regulation of insulin
expression [161]. Reports supporting the potential unhealthy effects of palm oil due to the high palmitic
acid content in the development of T2DM have suggested that chronic exposure of pancreatic islets to
palm oil inhibited glucose-induced expression of prepro-insulin, as well as Pdx1 and MafA expression,
causing β-cell failure [162,163]. The mechanism of downregulation of insulin gene expression by
palmitate involves the inhibition of PDX1 nuclear translocation, and therefore blocking MafA gene
expression [164]. Besides preproinsulin mRNA expression, palmitate also reduces Slc2a2 and Gck
probably through the inhibition of Pdx1 mRNA [165]. Elevated levels of fatty acids lipotoxicity have
been described to be mediated by de novo synthesis of ceramide which can be formed from palmitate
but not from oleate, explaining the fact that both palmitate and oleate inhibit insulin secretion but only
palmitate impairs insulin gene expression [166,167]. In addition, saturated fatty acid palmitate but
not unsaturated oleate, induces the activation of the NLRP3-ASC inflammasome causing caspase-1,
IL-1β and IL-18 production leading to reduced glucose tolerance and insulin sensitivity [168]. On the
other hand, monounsaturated fatty acid-enriched HFD improves insulin sensitivity in mice, attenuates
adipose IL-1β secretion and maintains adipose AMPK activation when compared to SFAs-HFD–fed
mice [169]. Moreover, we recently reported that an extra virgin olive oil intervention ameliorate
non-alcoholic steatohepatosis was induced by a high fat “Western-style” diet in mice [170]. Overall,
mice and in vitro experiments suggest that high levels of palmitate cause an alteration to genes
involved in lipid metabolism, inflammation and oxidative stress [171]. The possible mechanism of
SFAs to induce inflammation and IR in adipocytes, which would imply involvement of oxidative
stress through ROS in a toll-like receptor-4 and 2 (Tlr4, Tlr2), mediated inflammatory signalling.
Int. J. Mol. Sci. 2017, 18, 1188 12 of 40
Furthermore, activation of c-jun N-terminal kinase (JNK) also appeared to be essential to Tlr2-, as well
as Tlr4-induced IR and oxidative stress [172–174].
Intervention studies in humans where SFAs intake was reduced via replacement with unsaturated
fatty acids showed contradictory data that was observed in animal models: whilst some favored both
liver and visceral fat accumulation with a detrimental role in T2DM development and progression [175],
others showed improved insulin sensitivity but no effect on insulin secretion [176] whilst others showed
no significant effects [177]. Recently, the EPIC-InterAct case-cohort study in people with incident T2DM
reported that different SFAs have different effects on T2DM incidence [178]. Specifically, myristic,
palmitic, and stearic acids were all positively associated with incident T2DM while pentadecanoic
acid, heptadecanoic acid and arachidic acid were inversely associated with incident T2DM. Lauric,
myristic, and palmitic acids can raise total and LDL cholesterol, increase coagulation, induce IR,
and promote inflammation.
Regarding monounsaturated fatty acids (MUFAs), oleic acid has been suggested to improve glucose
control and insulin sensitivity [179]. The effects observed when replacing saturated fatty acids with
oleic acid may be due to partial removal of the SFAs biological effect, any constituent of the diet, or, to
the combination of foods/nutrients rather than to oleic acid. However, some studies indicate oleic acid
has some effects on transcription factors involved in lipid homeostasis, such as SREBPs [180]. Similarly,
palmitoleic acid also increases the transcription activity of SREBP1c, apart from enhancing the binding
of SREBP1c to FAS promoter and decreasing the phosphorylation of NF-κB, p65 and the expression of
proinflammatory cytokines [181]. In vitro approaches indicated that cis-palmitoleic acid can influence
pancreatic β-cell survival, insulin secretion, skeletal muscle insulin response and adipocyte metabolism,
On the other hand, prospective studies have shown a positive association between higher circulating
palmitoleic acid and improved insulin sensitivity or lower incident type T2DM [182,183].
T2DM is associated with increased blood concentrations of inflammatory biomarkers, including
C-reactive protein (CRP), which leads to a low-grade inflammation that is the mechanism underlying
IR. Epidemiological, human intervention, animal and cell culture studies have supported a beneficial
role for dietary n-3 polyunsaturated fatty acids (PUFAs) in low-grade chronic inflammation situations,
among others, by reducing CRP [184,185]. In overweight/obese patients with impaired fasting glucose
or impaired glucose tolerance, n-3 PUFAs reduced glycemia and fasting plasma insulin [186], while in
T2DM patients with omega-3 supplementation, a high ratio of eicosapentaenoic acid/docosahexaenoic
acid (EPA/DHA) contributed to a greater decreasing tendency in plasma insulin and HbAc1,
although with no statistically significant results [187]. The anti-inflammatory and preventive
inflammation-driven disease effect of n-3 PUFAs is related to NLRP3 inflammasome activation and
subsequent inhibition of caspase-1 activation and IL-1β secretion [188]. In addition, EPA has been
suggested to repress Srebp-1c, which may lead to a lower lipid accumulation in pancreatic cells and an
enhancement of insulin secretory mechanism [189,190].
Linoleic acid is the most prevalent omega-6 PUFAs in the human diet, found in some studies to
increase insulin sensitivity [191]. Although it has been shown to activate NF-κB [192], dietary intakes
were not associated with CRP, IL-6, soluble TNF receptor (sTNFR) 1, or sTNFR2 concentrations in
humans [193], therefore having only a limited effect on inflammation [194].
3. Diet-Gene Interaction and Risk of T2DM
For a decade, genome-wide association studies (GWAS) on T2DM have been conducted in a
variety of populations of different ancestries and more than 200 T2DM-related genetic variants have
been identified by GWAS so far [5,195]. Not all, but many of the gene variants found are located
in genes related to the insulin secretion pathway, insulin signalling, pancreatic β-cell dysfunction,
and IR pathway [196]. However, gene variants have been described in genes that apparently would
not be candidates for greater susceptibility to T2DM. In addition to the genetic architecture of T2DM
susceptibility, environmental factors are suggested to play a key role in the etiology of T2DM. Dietary
factors in particular may interact with genetic variants to modulate the risk of T2DM [197].
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All this makes it very complex to establish T2DM risk values according to allelic variants, due to:
(i) the existence of genetic variants that increase T2DM risk independently of the type of diet (ii) genetic
variants related to diet that modify some glucose metabolism systems, such as fasting glucose levels
and IR, but do not modify the risk of T2DM (iii) genetic variants that present a greater risk of T2DM
but this risk is modified depending on the type of diet (iv) genetic polymorphisms that modify risk
according to other parameters such as ethnic class and obesity. All this makes it somewhat difficult
to clearly establish cause-effect and therefore, the association between a gene variant and the risk of
developing T2DM.
3.1. Gene Variants Associated with Insulin Stimulus-Secretion Coupling and T2DM
Among the gene variants strongly associated with the risk of developing T2DM in various human
populations are several genes involved in the WNT-mediated signalling pathway, which induces
the expression of genes involved in pancreas development and in glucose homeostasis, such as
incretin-expressing genes that potentiate insulin secretion. One of the most important is the TCF7L2
gene encoding the transcription factor TCF7-like 2 located on chromosome 10 [198]. In several studies
in white European [199], Indian [200], Japanese [201], Mexican American [202], Chinese [203] and
African populations [204], TCF7L2 showed a strong association with the odds of developing T2DM
being increased by 30–50%. Several genetic polymorphisms have been described in the TCF7L2 gene
associated with an increased risk of T2DM (rs12255372 G<T, rs7903146 C>T), which interact with
the diet modifying susceptibility to T2DM. In this sense, it is important to differentiate between the
improvement in parameters related to glucose metabolism and the risk of T2DM. The Malmö Diet and
Cancer Study (MDCS) cohort conducted by Hindy et al. 2016 showed that high fibre intake improved
fasting plasma glucose and insulin levels, an improvement in IR values (HOMA-IR) and lower levels
of glycosylated haemoglobin. However, the T2DM risk in individuals carrying the risk allele TCF7L2
rs12255372 or TCF7L2 rs7903146 was higher when fibre consumption was high. In contrast, individuals
who did not carry the risk allele showed a decrease in T2DM risk with fibre intake [205].
No interaction was observed between polymorphisms and consumption of carbohydrates, fats or
proteins and the incidence of T2DM [206] in MDCS cohort.
On the other hand, an EPIC sub cohort study (EPIC-InterAct study) was carried out and an
interaction was noted between TCF7L2 variant rs12255372 and coffee intake, with an inverse association
between coffee consumption and T2DM among carriers of the diabetes risk allele (T) [207].
In MDCS cohort other allelic variants of genes encoding transcription factors involved in the WNT
signalling pathway with greater susceptibility to T2DM that is modified by the diet are ZBED3
rs4457053 G>A and NOTCH2 rs10923931 G>T in which fibre consumption protects against the
susceptibility to T2DM with higher fibre consumption in the risk allele carriers (T) for the case
of NOTCH2 and in individuals homozygous for the risk factor (GG) in the case of ZBED3 [205].
The protein encoded by the gene solute carrier family 30 (zinc transporter) member 8 (SLC30A8)
is a zinc efflux transporter protein necessary for the accumulation of zinc in intracellular vesicles.
The expression of this gene is very high in pancreas, especially in pancreatic islets. Zinc is required for
insulin biosynthesis and the maturation of insulin secretory granules [208]. Genetic polymorphisms
have been described in this gene that increase T2DM risk. Thus, the polymorphism rs13266634 C>T
was associated with lowered β-cell function and a 14% increase in diabetes abundance per risk (C)
allele [209]. A significant interaction between rs13266634 and serum levels of trans-β-carotene and
γ-tocopherol was identified. Higher levels of trans-β-catotene nutrient factor appeared to have a
protective effect in individuals with the risk allele. In contrast, high levels of γ-tocopherol produced
adverse effects in individuals with the risk allele [210]. Additionally, in a 14-cohort meta-analysis
study, an interaction was observed between the allelic variant SLC30A8 rs11558471 A>G, conferring
higher levels of fasting plasma glucose to A allele carriers, and zinc consumption. In a 14-cohort
meta-analysis study, total zinc intake had a stronger inverse association with fasting glucose levels in
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individuals carrying the glucose-raising A allele of rs11558471 SLC30A8, compared with individuals
carrying the G allele [211].
There exists a common genetic variant in the glucose-dependent insulinotropic polypeptide
receptor gene (GIPR rs10423928 T>A) which is related with a reduced insulin release and an increase
in T2DM risk. In the Swedish population-based Malmö Diet and Cancer cohort, it has been studied
the relationship between the mentioned genetic variant, macronutrients and fiber intake, body mass
index (BMI) and T2DM risk. It has been observed that when AA-genotype people follow high-fat,
low-carbohydrate diets, the T2DM risk decreases. On the other hand, two thirds of the people
homozygous for the T-allele resulted benefitted when they follow high-carbohydrate, low-fat diets [212].
A meta-analysis of 14 cohort studies for the interactions between the glucokinase regulatory
protein (GCKR) variant rs780094 G>A and whole grain intake demonstrated a possible relationship
between the gene variant and whole grain intake. In fact, people with the insulin-raising allele
rs780094 that followed a larger whole grain intake had a smaller reduction in fasting insulin compared
to subjects without the variant [213].
The S100A9 gene is located in region 1q21, a high susceptibility region to T2DM, and codes
for the calcium binding protein S100A9 (calgranulin B). The variant S100A9 (rs3014866 C>T) was
associated with protection against T2DM development in several populations, such as individuals
carrying the less frequent allele (T) who had a lower T2DM risk than those who did not carry the allele
(CC homozygous individuals). In the intervention trial study in 3 diverse populations (CORDIOPREV:
Coronary diet Intervention with Olive Oil and Cardiovascular prevention; GOLDN: Genetics of Lipids
Lowering Drugs and Diet network and BPRHS: Boston Puerto Rican health Study) related to the
interaction of polymorphism with diet, individuals with the non-protective variant (CC) had a higher
HOMA-IR value than individuals carrying the allele (T) when the association between intake of
saturated fatty acids (SFAs) versus carbohydrates was high, and that this difference disappeared when
intake of SFAs/carbohydrates was low [214]. This may be one of the reasons why individuals with the
CC polymorphism are at increased risk of T2DM and that diet may reduce this risk.
The transient receptor potential vanilloid 1 (TRPV1) gene is involved in energy and glucose
metabolism. TRPV1 activation increases insulin sensitivity and potentiates glucose-stimulated insulin
secretion. A Korean Genome Epidemiology Study demonstrated that individuals with the minor
alleles of the TRPV1 single nucleotide polymorphisms (SNPs) rs161364 T>C and rs8065080 T>C were
negatively associated with the prevalence of T2DM. They also determined that carriers of the minor
allele of both SNPs have a lower risk of diabetes with a high-fat diet but individuals with the major
alleles are at a higher risk of T2DM when consuming high-fat diets [215].
In a small case-control study examining interactions between magnesium intake and loci in
TRPM6 (transient receptor potential cation channel, subfamily M, member 6) associated with T2DM, in
older women carried out over 10 years, it reported that women who were carriers of 2 rare alleles from
nonsynonymous SNPs in TRPM6 (rs3750425 and rs2274924) had nearly 5 times the odds of T2DM
when their magnesium intake was less than 250 mg/d [216].
The SNP rs3786897 G>A in the peptidase D (PEPD) gene has been associated with the risk of
T2DM in Asian individuals [217]. PEPD protein plays an important role in the recycling of collagen
metabolisms, while it is shown to have a profound impact on β-cell function [218]. In a case-control
study examining the genetic effect of the PEPD rs3786897 A allele on the risk of T2DM may be abolished
when n-3 PUFA intake is high [219] (Table 3).
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Table 3. List of gene-nutrient interactions in the development of T2DM.
Genes Related with Stimulus-Secretion Coupling




MDCS cohort/fibre intake Higher risk in individuals carrying the allele-T.Smaller risk in individuals homozygous GG [205]
EPIC InterAct study/Coffee Intake Smaller risk in individuals carrying the allele-T [207]
rs7903146 C>T Allele-T riskincrease MDCS cohort/fibre intake
Higher risk in individuals carrying the allele-T.
Smaller risk Individuals homozygous CC [205]
ZBED3 rs4457053 G>A Allele-G riskincrease MDCS cohort/fibre intake
Smaller risk in individuals homozygous
for the risk factor (GG) [205]
NOTCH2 rs10923931 G>T Allele-T riskincrease MDCS cohort/fibre intake Smaller risk in individuals carrying the allele-T [205]
SLC30A8
rs13266634 C>T Allele-C risk
increase
NHANES cohort study/
trans-β-carotene intake Smaller risk in individuals carrying the allele-C [209,210]
NHANES cohort study/







Smaller levels of fasting plasma glucose in
individuals carrying the allele-A [211]
GIPR rs10423928 T>A Allele-A riskincrease
MDCS cohort/fats and
carbohydrates intake
Smaller risk in individuals homozygous for de risk
factor AA consuming high-fat, low-carbohydrate
diets.
High-carbohydrate, low-fat diets benefit of the
population homozygous for the T-allele
[212]
GCKR rs780094 C>T Allele-T riskincrease
14-cohort meta-analysis
study/whole-grain intake Smaller risk in individuals carrying the allele-T [213]
S100A9 rs3014866 C>T Allele-T riskdecrease
Intervention trial in CORDIOPERV,
GOLDN and
BPRHS/SFAs:carbohydrates ration
Ration high: Individuals with the non-protective
variant (CC) had a higher HOMA-IR.
Ration low: Individuals with the non-protective
variant (CC) had a normal HOMA-IR.
[214]
TRPV1
rs161364 T>C Allele-C risk
decrease
Cohort study/high fat diet intake Smaller risk in individuals carrying the allele-C
Higher risk in individuals carrying the allele-T [215]rs8065080 T>C
TRPM6




Higher risk in women carrying the allele-T [216]
rs3750425 C>T
PEPD rs3786897 G>A Allele-A riskincrease
Cases-control study/
High n-3 PUFAs
The risk disappears in individuals
carrying the allele-A [219]
Genes Related with Insulin Signaling
Gene SNP T2D Dietary Factors Effect of Interaction betweenSNP and Dietary Factors References
PPAR-γ rs180282 C>G Allele-G riskincrease
DESIR cohort study/high
fat intake increases Higher risk in individuals carrying the allele-T [220]
ADIPOQ rs1501299 G>T
Allele-T risk
increase Cohort study/carbohydrate intake
Higher fasting blood glucose and HbA1C
concentrations in individuals carrying allele-T [221]
rs2241766 T>G Allele-G riskincrease
MARINA trial study/




of IR and lower
fasting insulin
GOLDN and BPRHS cohort
studies/low total fat and
SFA:carbohydrate ratio intake
Decrease resistance to insulin and plasma insulin [223]
rs2943641 C>T
Allele-T lower risk
of IR and lower
fasting insulin
GOLDN and BPRHS cohort
studies/low fat and
SFA:carbohydrate ratio intake
Decrease resistance to insulin and plasma insulin [223]
Cohort study/vitamin D intake Smaller risk in individuals carrying the allele-T [224]
CAV2 rs2270188 G>T Allele-T riskincrease
Cases-cohort study/high fat or SFA
intake Higher risk in individuals carrying the allele-T. [225]
Other Genes
Gene SNP T2D Dietary Factors Effect of Interaction betweenSNP and Dietary Factors References
FTO
rs9939609 T>A Allele-A riskincrease
Cases-control study/adherence to
Mediterranean diet
The risk disappears in individuals
carrying the allele-A [226]
rs8050136 C>A Allele-A riskincrease
Cases-control study/adherence to
Mediterranean diet
The risk disappears in individuals
carrying the allele-A [226]
CLOCK rs4580704 C>G Allele-G riskdecrease
PREDIMED trial study/high
MUFA intake Lower risk in individuals carrying the allele-G [227]
CRY1 rs2287161 G>C Allele-C riskincrease
Cohorts Mediterranean and North
American study/high
carbohydrate intake
Increase in HOMA-IR index, fasting insulin and a
decrease in QUICKI [228]
MC4R rs17782313 T>C Allele-C riskincrease
Systematic review study/adherence
to Mediterranean diet
The risk disappears in individuals
carrying the allele-C [226,229]
PLIN rs11482 G>A Allele-A riskincrease
cross-sectional
study/SFAs:carbohydrates ration
Ration high: women homozygous for
AA increased HOMA-IR [230]
FABP2 rs1799883 G>A Allele-A riskincrease
11-cases-control meta-analysis
study/MUFA intake Decrease in HOMA-IR index [231]
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3.2. Gene Variants Related to IR and T2DM
Peroxisome proliferator-activated receptor-γ (PPAR-γ) is a transcription factor that directly
regulates target genes, mediating lipid metabolism and adipocyte differentiation. The genetic variant
Pro12Ala rs180282 in PPAR-γ has been associated with the T2DM risk and BMI [232]. The less
frequent PPAR-γ Ala12 variant reduces the risk of T2DM and is positively associated with insulin
sensitivity. DESIR (Data from an Epidemiological study on the Insulin Resistance Syndrome) cohort
study indicates high fat intake increases T2DM risk in Pro homozygous individuals [220].
Adiponectin (encoded by ADIPOQ) is an important adipocytokine that is secreted by adipocytes
and plays a key role in the inflammatory response that is associated with insulin-resistant states and
T2DM. In recent years, the association between SNPs of the ADIPOQ gene and T2DM has been reported
in the Asian population in particular [233]. Interactions of variants of the adiponectin gene with
carbohydrate intake [29] and fat intake [30] have been explored. Significant dose-response interactions were
identified between the ADIPOQ rs1501299 G>T polymorphism and the dietary intake of carbohydrates
in a prospective study of 673 patients with T2DM. This previous study demonstrated a connection
between the gene-nutrient interactions of rs1501299 G>T polymorphism and the level of carbohydrate
intake modulating fasting plasma blood glucose and glycosylated hemoglobin [221]. Other gene-nutrient
interactions include rs2241766 T>G and a diet high in n-3 PUFAs. The MARINA trial study demonstrated
that individuals who had a high intake of n-3 PUFAs showed a decreased risk of T2DM [222].
The IRS1 gene encodes insulin receptor substrate 1 (IRS1), a protein central to insulin signalling
pathways. Two genetic variants (rs7578326 and rs2943641) near IRS1 were identified by GWAS to be
associated with T2DM [223,234]. IRS1 variants rs7578326 G allele and rs2943641 T allele were associated
with a lower risk of IR and lower fasting insulin in two independent populations of different ancestries
(GOLDN cohort study and the BPRHS cohort study). These associations appeared to be modulated
by dietary factors, especially the dietary SFAs-to-carbohydrate ratio, MUFAs, and carbohydrate
quantity and quality. Thus, low consumption of MUFAs, low total fat consumption and a low SFAs to
carbohydrate ratio decrease resistance to insulin and plasma insulin, but not when consumption is
high [223]. Another longitudinal cohort study also explored the relationship between IRS1 rs2943641
and circulating levels of 25-hydroxyvitamin D 25(OH)D. Puerto Rican adult females homozygous for
the minor allele rs2943641T with higher circulating 25(OH)D showed a lower risk of IR and T2DM
compared to carriers of the major allele (C) [224].
The CAV2 gene encode the major protein components of caveolae. These are invaginations
of the plasma membrane. These proteins are important for several cellular functions as signal
transduction, lipid metabolism, cellular proliferation, apoptosis, differentiation and trafficking.
The case-control study of the European prospective Investigation into Cancer and Nutrition-Post
dam cohort demonstrated a significant relationship between the CAV2 rs2270188 G>T polymorphism
and fat and SFAs intake with respect to T2DM. Homozygous individuals of the rare T-allele showed
a 100% greater risk of T2DM when daily fat intake was increased from 30% to 40% in energy value,
and an increase in dietary SFAs from 10% to 20% energy value predicted approximately 200% greater
risk of T2DM. However, homozygotes for the G allele and heterozygotes do not have increased risk of
T2DM with higher fat or SFAs consumption [225] (Table 3).
3.3. Other Genetic Variants and T2DM
The fat mass and obesity-associated gene (FTO) is located on chromosome 16 and contains nine
exons. Actually, it has been described several SNPs of this gene that have been regularly associated
with obesity risk. Nevertheless, there isn’t a consistent association between obesity risk alleles and
T2DM. A meta-analysis of 62 case-control studies from different regions (including Asia, Europe
and North America) demonstrated that the rs9939609 T>A and rs8050136 C>A SNPs contributed to
an increased risk of T2DM [235]. A case-control study, with 3430 T2DM patients and 3622 healthy
people without difference in their BMI, showed steady gene-diet interactions with adherence to the
Mediterranean diet for individuals carrying the FTO-rs9939609 variant. Moreover, in the presence of a
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low Mediterranean diet adherence, people of the variant alleles showed a higher T2Dm risk. On the
contrary, with a high Mediterranean diet adherence, these associations were not observed [226].
Dysregulation and genetic variations in the Circadian Locomotor Output Cycles Kaput genes
(CLOCK), which are responsible for the circadian system, have been associated with T2DM [236].
A longitudinal study, undertaken with 7098 participants in the PREDIMED trial analysed the
association between the SNP CLOCK rs4580704 C>G and the incidence of T2DM. G-allele carriers
presented lower T2DM risk than CC homozygous subjects. The protective association of the G-allele
against T2DM incidence was stronger and of higher statistical significance in the Mediterranean diet
(High MUFAs) intervention group than in the control group (Low MUFAs) [227]. The interaction
between the cryptochrome 1 (CRY1) rs2287161 G>C variant and several diabetes-related traits (fasting
glucose and insulin, HOMA-IR and QUICKI index) has been studied in The Mediterranean and North
American Cohort. The authors showed that a significant increase in HOMA-IR index and fasting
insulin, as well as a decrease in QUICKI was associated with a higher carbohydrate intake in people
homozygous for the minor C allele [228].
The melanocortin-4 receptor (MC4R) gene is a receptor for the α-melanocyte stimulating hormone
(α-MSH) which regulates food intake and energy homeostasis. In a systematic review study a
consistent interaction between adherence to a Mediterranean diet and the MC4R rs17782313 T>C was
demonstrated. When adherence to the Mediterranean diet was low, carriers of the variant allele for
MC4R rs17782313 (C) had a higher risk of T2DM than homozygous participants for the major allele (T).
When adherence to the Mediterranean diet was high, however, there was no association between this
polymorphism and T2DM [226,229].
The Perilipin gene (PLIN) regulates adipose metabolism and has been associated with several
risk factors for diabetes, including obesity, weight gain and IR, in both American [237] and Chinese
women [238]. Although an interaction between the allelic variants and an increased risk of T2DM has
not been found, the analysis of the interaction between these variants and diet showed a significant
gene-diet interaction between the PLIN 11482 G>A and the PLIN 14995 A>T polymorphisms with
dietary fat and carbohydrate intake. A cross-sectional study of Asian women with these SNPs showed
women homozygous for the minor allele A are at increased insulin resistance when SFA intake is high
and carbohydrate intake is low. Notably, these gene-fat interactions were observed only for SFAs,
but not for MUFAs or PUFAs [230].
Intestinal fatty acid-binding protein 2 (FABP2) Ala54Thr polymorphism (rs1799883) is associated with
risk of T2DM. Carriers of the Thr54 allele are more susceptible to T2DM than those which are homozygous
for Ala54 [231]. Fat intake and insulin sensitivity have also been studied [239] and it was shown that
insulin sensitivity improved in subjects with the Thr54 allele of the FABP2 polymorphism when SFAs were
replaced by MUFAs and carbohydrates in 11 case-controlled meta-analysis studies (Table 3).
4. The Role of Epigenetics in the Onset of T2DM
As previously mentioned, T2DM occurs as a consequence of the interaction between genetic
and environmental factors. One of the most important environmental factors to consider is diet.
GWAS have identified about 100 loci that influence the risk of developing T2DM. Most of them are
responsible for alterations in the development of pancreatic islets and/or their function and only a
few act through insulin signalling [240]. However, these variants have a reduced effect on the risk of
T2DM and are only able to explain at most 10–15% of T2DM inheritance [4]. Thus, if T2DM is a disease
in which the hereditary component is important and the genetic variants can explain only a minimal
part of that inheritance, this means epigenetic modifications could explain the relationship between
environmental factors and the risk of developing T2DM. The proposed explanation is that epigenetic
changes occurring throughout life caused by environmental factors (such as diet) can modify gene
expression and affect susceptibility to T2DM. In this regard, one of the major changes that has occurred
in the Western world and that undoubtedly contributes to the increase in the prevalence of T2DM is an
increased caloric intake and reduced energy expenditure, the latter caused by a sedentary lifestyle.
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Epigenetics is a form of genomic control that produces changes in the structure of chromatin,
without generating changes in the DNA sequence. These changes in chromatin originated by external
stimuli are capable of activating or silencing gene expression. There are three types of epigenetic
mechanisms: (i) DNA methylation; (ii) post-transcriptional modification of histones; (iii) Mechanisms
based on non-coding RNA (microRNA & long non-coding RNA). The first modifies the accessibility
to the genes by inducing transcriptional repression. The second includes acetylation, methylation,
phosphorylation, ubiquitination and SUMOylation of certain histone amino acids. These processes
induce chromatin condensation and consequently, the phenomena of gene activation and/or silencing.
Finally, non-coding RNAs can regulate gene expression by acting on the protein synthesis machinery
at the translational and post-transcriptional levels. Of special note is the role of microRNAs (miRNAs)
and long non-coding RNAs (LncRNAs). Numerous studies have shown that epigenetic modifications
are able to induce IR and damage β-cells, thereby causing insufficient insulin release and T2DM [241].
It has been established in experimental studies that patients with T2DM have reduced β-cell
mass [242]. In addition, this is known to occur due to external factors, sometimes of a nutritional
nature and may make it difficult to maintain the state of differentiation of β-cells. The control of β-cell
mass during development and in adulthood is regulated by master genes that act as a balance to
regulate β- and α-cell mass. In this regard, paired box gene 4 (Pax 4) is necessary for the existence
of mature β-cells and Arista-less-related gene homeobox (Arx) for the formation of α-cells [243].
Thus, in an experimental study with pancreatic islets from patients with T2DM, the PAX4 gene is
hypermethylated and therefore silenced [244]. In contrast, in rodents, the Arx gene is methylated
and repressed in β-cells [245]. Variations in DNA methylation also affect insulin release processes.
For example, the incretin hormone glucagon-like peptide-1 (GLP-1) increases insulin release acting
through its receptor (GLP1R). It has been confirmed that in isolated pancreatic islets of patients with
T2DM, hypermethylation of the GLP1R gene occurs, thus reducing its expression [246].
Post-transcriptional modifications of histones are also able to regulate β-cell mass. It has been shown
that in animals lacking histone deacetylase 5 and 9 expression, β-cell mass is increased. Conversely,
in mice, with increased deacetylase 4 and 5 expression, there is decreased β-cell mass [247]. Moreover,
it is known that although β-cell mass is established before adulthood, it can be modified according to
metabolic demands, such as obesity and pregnancy. Indeed, failures in this compensatory capacity can
lead to the onset of diabetes [248]. Interestingly, epigenetic modifications can regulate this adaptive
proliferation response. This would be done, as it has been demonstrated in mice, by modifying
the expression of the cyclin dependent kinase inhibitor 2A gene (Cdkn2a) by post-transcriptional
modifications of histones [249]. Another fundamental master gene for the maintenance of the β-cell
phenotype, and for its correct functioning, is Pdx1. It has been shown in mice that the association between
this gene and the histone deacetylases varies according to the levels of circulating glucose [250]. Histones
also play a role in insulin secretion in response to glucose. For example, histone methyltransferase Set7/9
promotes the expression of important genes such as v-maf musculoaponeurotic fibrosarcoma oncogene
family, MafA and Slc2a2 for insulin secretion. In fact, a depletion of Set7/9 in mouse pancreatic islets
induces a decrease in insulin release in response to glucose [251].
miRNAs regulate processes related to insulin signalling as well as inflammatory processes. Both
phenomena are directly involved in the onset of IR. The role of miRNAs in the development of IR and
the onset of T2DM has been studied in different metabolic tissues (liver, adipose, muscle and pancreas)
both in humans and mice. In addition, it has been suggested that the microvesicular transport of
miRNAs could be a mechanism by which miRNAs act as local and systemic mediators of IR [252].
Studies indicate that the miRNA 143–145 cluster intervenes in IR produced by obesity. Mice that
do not express this cluster are protected against IR induced by obesity caused by a high caloric
intake. In contrast, conditioned overexpression of miRNA worsens obesity-induced IR [253]. The let-7
family of miRNAs also participates in the regulation of IR. Mice fed a HFD and overexpression
of let-7 had impaired glucose tolerance and IR, despite having normal insulin production and
secretion levels [254]. Moreover, the administration of anti-miRNA let-7 partially diminished the
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effects of HFD on IR in experimental studies on mice and humans [255]. The miRNA 200 family
also participates in the regulation of insulin sensitivity. Specifically, inhibition of miRNA 200a in
the hypothalamus of ob/ob mice increases leptin receptor expression, decreasing body weight and
increasing insulin sensitivity [256]. miRNA 223 knockout mice exhibit higher IR when fed an HFD.
In addition, they present a higher degree of inflammatory stress [257]. It has been known for several
years that the miRNA29 family negatively regulates the insulin signalling pathway in adipocytes [258].
In addition, increased miRNA29 expression in the livers of diet-induced obese mice and Zucker
diabetic rats has been demonstrated. Most interestingly, miRNA29 levels were normalised after
treatment with pioglitazone, in both models [259]. miRNA 375 is particularly important for blood
glucose regulation. It is expressed at high levels in β-cells, contributes to the maintenance of the β-cell
phenotype and enhances insulin synthesis in IR mouse models. In this respect, ob/ob mice show
increased miRNA 375 expression. Conversely, mice lacking miRNA 375 have low insulin synthesis and
hyperglycemia [260,261]. In addition, experimental studies have shown that miRNA 375 is abundantly
expressed during human pancreatic islet differentiation [262].
Aside from dietary modifications, certain nutrients are capable of affecting miRNA expression.
It is known that chronic hyperglycemia and hyperlipidemia are capable of modifying gene expression
and inducing β-cell damage or dysfunction leading, ultimately, to apoptosis. This process is known as
glucotoxicity and lipotoxicity. Excess glucose and fatty acids lead to stress on the rough endoplasmic
reticulum of the β-cells, which in turn causes an increase in the production of reactive oxygen
species (ROS) [263]. In other tissues it has been shown that ROS can induce modifications in DNA
methylation [264], which could also occur in β-cells. Elevated levels of glycosylated hemoglobin
indicating a chronic blood glucose elevation, have been found to correlate positively with increases in
methylation of the promoter regions of the INS and PDX1 genes in human pancreatic islets [265,266].
Regarding miRNAs, it has been shown in rat pancreatic islets that prolonged exposure of β-cells to
SFAs, such as palmitate, increases the expression levels of miRNA 34a and miRNA 146a [267]. Also,
glucose is able to modify the expression of miRNA 9, 30d, 124a, 130a, 132, 133, 212 and 335 [268].
4.1. Epigenetic Modifications as Biomarkers of T2DM
Epigenetic modifications can be used as epigenetic biomarkers to detect recent β-cell death.
In experimental studies, in mice and humans, it has been shown that the insulin promoter has low
methylation levels in endocrine cells, but its methylation level is higher in the rest of the cells in the
body [269]. Dying cells release genomic DNA into the bloodstream. When a high proportion of lowly
methylated versus highly methylated insulin promoter is found, this is an indicator of recent β-cell
death [3]. In the GOLDN Cohort, it was observed that the methylation levels of the ATP binding
cassette gene subfamily G member 1 (ABCG1, important for cholesterol transport) were significantly
associated with fasting insulin levels and IR values in patients with T2DM [270]. In an observational
study in the Twins-UK Cohort, it was noted that methylation changes occurred in mucosa-associated
lymphoid tissue lymphoma translocation gene 1 (MALT1) and G-protein receptor 6 (GPR6) gene
which indicated T2DM progression [271]. Different degrees of DNA methylation in the adipose tissue
of patients with T2DM compared to healthy individuals has been found in peroxisome proliferator
activated receptor gamma (PPAR-γ), insulin receptor substrate 1 (IRS1) and transcription factor 7-like
2 (TCF7L2) genes [272]. Finally, decreased methylation of the septin 9 (SEPT9) gene has been identified
in an experimental study using pancreatic islets of patients with T2DM [273].
The presence of miRNAs have also been proposed as potential biomarkers for different diseases
including T2DM. This idea is supported by several facts: (i) They are present in human fluids
(e.g., plasma, serum, urine, saliva and tears); and (ii) They are very stable at room temperature
and show good resistance to freeze-thaw changes. In T2DM there is the additional advantage that
compared to other traditional biomarkers (blood, glucose and insulin levels), certain miRNAs have a
greater postprandial stability [252]. Nonetheless, the use of miRNAs as biomarkers of T2DM poses
three problems. The first is that it is very difficult to determine the precise origin of most circulating
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miRNAs. Because pancreatic islets make up a tiny fraction of our body’s cells, the amount of plasma
miRNAs that come from the pancreatic islets is probably negligible. Secondly, the expression of a
specific miRNA is affected by numerous physiological and pathological conditions and, accordingly,
it varies. Finally, it is important to have information that relates the plasma miRNAs to SNPs associated
with T2DM. Studies are beginning to appear that lead us to believe that miRNAs could be used as
biomarkers of T2DM. It has been shown that members of the let/7 family of miRNAs are able to
modulate insulin sensitivity and glucose metabolism. A nutritional intervention study found that in
healthy young women, reducing the dietary glycemic load increased plasma levels of let-7b by up to
eight times [274]. In addition, plasma values of let-7a and 7f are significantly lower in patients with
T2DM. In a case-control study, it was found that in treated patients, the levels were normalised when
compared to those of the control subjects [275].
4.2. Fetal Developmental Memory
It is known that a large portion of epigenetic footprints are established during the fetal
development period. Thus, an adverse intrauterine environment can be “memorized” by generating
specific methylation patterns. These patterns may increase the risk of developing T2DM in adulthood,
something akin to “metabolic reprogramming”. Within the impact of maternal nutrition, it is important
to consider the lipid profile, circulating blood glucose, overweight and obesity, and malnutrition.
The proposed explanation is that transient nutritional changes occurring throughout the prenatal
period, and possibly affecting the future risk of developing T2DM, are produced as a consequence of
epigenetic changes. This hypothesis is based on three assumptions: (i) Epigenetic modifications can
occur in response to environmental factors, including food; (ii) Epigenetic changes can be maintained
stable throughout life; (iii) These changes can be transmitted to the next generation through gametes.
In animal models, the effects of different nutritional models on the development of T2DM
in the F1 and F2 generations have been studied in young female rodents in gestation and during
lactation. The nutritional models usually employed are low protein diets, caloric malnutrition and
HFD, although other animal models include intrauterine growth retardation (IUGR). Thompson et al.
(2010) found that the pancreatic islets of rats subjected to IUGR have an alteration in gene expression,
together with different methylation patterns at approximately 1400 CpG sites [276]. In this same IUGR
model, a permanent reduction in Pdx1 expression is produced in β-cells due to epigenetic changes
occurring during development. This reduction in Pdx1 expression has been correlated with the onset
of T2DM [277]. On the other hand, Sandovici et al. [278] found that when low protein diets were fed to
rats during pregnancy and lactation, there was an increase in methylation of Hnf4α gene promoter,
as well as a reduction in the active marks of histone H3 (H3K3me) acetylation in pancreatic islets.
Furthermore, the glucose intolerance produced in mice subjected to a caloric malnutrition model is
transmitted to the F1 generations and not to the F2 generations [279]. This is due to the appearance of
different regions that are methylated and are resistant to epigenetic erasure during the early stages
of embryogenesis [280]. In HFD models maintained during pregnancy, an increased risk of obesity
and T2DM has also been observed. When female mice were fed an HFD from the fourth week prior to
pregnancy until the end of lactation, male mice born in the first generation developed obesity and IR
when they reached adulthood [281]. Another widely used model to study fetal environment effects on
the development of T2DM includes the induction of gestational diabetes in pregnant females in order to
generate a hyperglycemic environment in the uterus. In this case, the offspring of these mothers had a
defect in insulin secretion leading to glucose intolerance. In addition, the male offspring of the females
born in an environment of intrauterine hyperglycemia also developed the same phenotype [282].
In both cases, the defective insulin secretion was due to hypermethylation of the DNA methylation
region, together with a concomitant reduction in the expression of insulin growth factor-2 and H19.
Although there is less information available, there is one study that identifies the existence of
a possible “metabolic reprogramming” of paternal origin. Ng et al. crossed male rats subjected to a
HFD with control female rats and found that their offspring had altered β-cell function as well as a
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differential expression of 642 genes in their pancreatic islets [283]. Moreover, the study by Dunn et al.
found that the second generation of male offspring also developed the same alterations [284].
The existence of transmission of a metabolic phenotype mediated by dietary modifications up to the
second generation and through the paternal line suggests that epigenetic mechanisms are contributing
to this process. To verify whether this generational transmission of phenotypes is mediated by
epigenetic factors linked to the germ line, Dunn et al. analysed the F3 generation phenotypes. It was
found that the F3 generation females, who were born to the F2 generation males, also showed the same
phenotype [281]. Another study also indicates that the induction of HFD-mediated obesity in male mice
causes glucose intolerance in their offspring [285]. Finally, in models where prediabetes was induced
(with HFD and low-dose of STZ) in male mice, their offspring developed IR and glucose intolerance.
When studying gene expression in the islets, a differential expression of 402 genes in the islets of the
offspring was found. In addition, when genome-wide DNA methylation analysis was performed there
were more than 800 regions showing different methylation patterns in the islets of the offspring. Most
interestingly, this study demonstrated that prediabetes in the fathers altered methylation patterns in
their sperm. Finally, a significant portion of the hypermethylated and hypomethylated intragenic
regions overlapped in the sperm and pancreatic islet cells.
In humans, the most solid data comes from the analysis of what occurred during the famine in
Holland between 1944 and 1945. There was a period of approximately five months during which
there was a significant food restriction that affected pregnant women in different periods of their
gestation. In addition, these women had adequate food before and after this short period. The study
and follow-up of the children, after reaching adulthood, who were affected by this famine during their
intrauterine life provides much information on how feeding in the prenatal period may subsequently
affect the risk of developing T2DM.
The cohort study of Ravelli et al. showed that adults who were born near this period of famine had
lower glucose tolerance. The authors of this study concluded that poor intrauterine nutrition could cause
permanent changes in the glucose homeostasis process and that these changes were much more evident
when those individuals developed obesity [286]. Subsequently, De Rooij et al. found, in the Dutch Famine
Birth Cohort, that this glucose intolerance was mediated by a defect in insulin secretion [287]. Moreover,
it has been proven, in the cohort study of Hillier et al. that the impact of such alterations can even be
transmitted to the next generation [288]. In a recent study in a cohort of people exposed to famine in
Bangladesh during their intrauterine developmental stage, their increased predisposition to T2DM was
shown to be due to epigenetic changes (mainly changes in DNA methylation). These epigenetic changes
vary according to the intrauterine development time frame during which famine was experienced [289].
A similar conclusion was reached by Heijmans et al., in the Dutch Hunger Winter Families Study [290].
In addition, these authors found that the effects of famine on epigenetic modifications were more critical if
famine occurred during the embryonic developmental period.
Furthermore, studies in the Dutch Famine Birth Cohort found that when the fetuses were subjected
to insufficient feeding during any period of their gestation, there was an increase in the LDL:HDL ratio
upon reaching adulthood [291]. This increases the risk of developing T2DM, as it is well established
that an increase in LDL levels predisposes to T2DM.
In contrast, a population-based cohort study with women who develop obesity during pregnancy,
have IR. The excess nutrients consumed by the mother reach the fetus which in turn releases its own
insulin, thus increasing the fetal uptake of glucose and fats causing these infants to be born with a
higher weight [292]. When these children reach adulthood, they are exposed to an increased risk of
developing obesity and T2DM. Studies by Wellen et al. indicate that in cell culture lines, the ATP-citrate
lyase enzyme is essential for histone acetylation [293]. This enzyme is critical in the conversion of
citrate through glycolysis into acetyl-CoA. Curiously, the acetylation of histones is more evident in
periods when there are sufficient glucose inputs. There is another historical cohort from Northern
Sweden (Överkalix cohort) that demonstrates that overfeeding in children may increase the risk of
T2D in their grandchildren [294]. Finally, as occurs with male rats, a historical cohort study based on
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the Dutch Famine Population showed that the children of men who experienced prenatal malnutrition
are more obese and therefore at greater risk of developing T2DM [295].
5. Conclusions
T2DM is a multifactorial disease which arises from complicated interactions between the genetic
makeup and environmental factors. Among these factors, many studies (experimental, case-control,
cohort and nutritional interventions) have shown the impact of diet on the development of T2DM.
Several cohort studies have also shown that diet can generate epigenetic modifications throughout
the lifetime that affect gene expression and consequently, susceptibility to T2DM. Moreover, these
epigenetic modifications might play a relevant role in the inheritance of T2DM.
Nutrition is a very important factor that modulates expression of genes involved in metabolic
pathways related to T2DM pathogenesis. As previously discussed, different macro and micronutrients,
as well as food bioactive compounds positively affect the expression of genes involved in insulin
synthesis, stimulus-secretion coupling, protection of β-cells against gluco-lipotoxicity, inflammation
and oxidative stress, and IR. However, this jigsaw is not so easy to solve. Nutrigenetics give us the
shape of the pieces, but we still need the drawing of the pieces of the puzzle and the resulting picture
we want to reproduce.
The information about the pieces is provided by nutrigenomics. Linkage analysis, candidate
gene approaches, genome-wide association studies and sequencing have provided us with plenty of
information that allows a better understanding of the genetic landscape of T2DM. This disease has a
strong genetic predisposition and the discovery of the existence of genetic variants associated with
T2DM and their related traits has shed light on the different individual risks. There are cohort and
nutritional intervention studies showing that people with higher genetic predisposition should avoid
particular dietetic patterns that are more harmful in the variation of a specific T2DM-related phenotype.
The picture to be reproduced in our puzzle appears when the epigenetic factors come into the
scene. Nutrigenetics and nutrigenomics are not able to completely explain the complex relationship
between environmental factors and genetic susceptibility to T2DM. In fact, the overall risk explained
by genetic variations is small. Epigenetic could be the missing link that gives shape to the puzzle.
The rational is that nutrients and dietetic patterns experienced during one’s lifetime, including the
prenatal and neonatal periods, induce epigenetic modifications that affect gene expression and change
the individual disease risk present in our genetic makeup (Figure 1). In addition, these epigenetic
modifications could be behind the possible transgenerational inheritance of T2DM.
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